At present, several oral antidiabetic medications are used for the treatment of T2DM including, -glucosidases inhibitors, biguanides, sulfonylureas, meglitinides, GLP-1 receptor agonists (GLP-1RAs), peroxisome proliferator-activated receptor (PPAR-) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodiumglucose transporter 2 (SGLT2) inhibitors
Some studies point to possible underreporting because symptoms don't always follow typical patterns
Stage 2 (emerging, 2025-2030): Continuous bioprocessing
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Retatrutide has the higher observed ceiling, a mechanistically broader target profile, and two network meta-analyses that point in its direction 20 21